Endpoints News
Cor­morant eyes an­oth­er $400M health­care fund Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T Wed Th F
26 November, 2025
ENDPOINTS at #JPM26
Biopharma’s year doesn’t start on January 1. It starts in San Francisco. Join Endpoints for bold conversations with the leaders shaping what's next. Plus, get access to the Endpoints Hub — our premium coworking and meeting space just steps from the action. Save $200 with Early Bird rates — reserve your spot today.
presented by etcembly
Start smarter, dis­cov­er faster: EM­Ly Co-pi­lot, an AI-dri­ven bi­o­log­ics dis­cov­ery plat­form
top stories
1. China biotech seeks to rewire eye cells to create ‘one-size-fits-all’ rival to Luxturna
2. Cormorant eyes another $400M healthcare fund
3. FDA pushes back Ascendis' dwarfism drug decision date by three months
4.
news briefing
Imfinzi's latest label expansion; FDA seeks more information on BiomX's nebulizer
5. Sanofi headquarters raided in broader French tax fraud investigation
6. Updated: CMS unveils negotiated prices for Ozempic, Wegovy and other drugs from second round of IRA talks
7. Kallyope scraps one of two mid-stage migraine drugs
8. Otsuka’s anti-APRIL antibody gets FDA approval for kidney disease IgAN
more stories
• 
Drew Armstrong
.

With the Thanksgiving holiday in the US, Endpoints won't be publishing our newsletters on Thursday and Friday. If you're celebrating, we hope you have a wonderful meal with family and friends.